This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Universal Health (UHS) Q1 Earnings & Revenues Lag Estimates
by Zacks Equity Research
Universal Health (UHS) posts a solid Q1 driven by higher revenues.
Amgen (AMGN) Earnings Beat Estimates in Q1, Revenues Up Y/Y
by Zacks Equity Research
Amgen (AMGN) impresses with better-than-estimated results on both counts but tweaks its sales guidance for 2018. Shares decline in after-hours trading.
Drug Stock Q1 Earnings Due on Apr 26: ABBV, ALXN, BMY & VRTX
by Zacks Equity Research
Four pharma/biotech companies are set to release earnings report on Apr 26. Let's take a look into how the companies are placed ahead of the upcoming results.
Anthem (ANTM) Beats on Q1 Earnings, Raises '18 Guidance
by Zacks Equity Research
Strong performance across segments supports Anthem's (ANTM) first-quarter results.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Honeywell, Morgan Stanley, Novartis and eBay
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Honeywell, Morgan Stanley, Novartis and eBay
Centene (CNC) Q1 Earnings & Revenues Top, '18 View Lowered
by Zacks Equity Research
Centene (CNC) delivers strong first-quarter results on the back of significant membership growth.
Top Research Reports for Johnson & Johnson, Honeywell & Morgan Stanley
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Honeywell (HON) and Morgan Stanley (MS).
Drug/Biotech Stock Q1 Earnings Due on Apr 24: LLY, BIIB, AMGN
by Zacks Equity Research
Three pharma/biotech bigwigs are set to release earnings report on Apr 24. Let's sneak a peek into how the companies are placed ahead of the upcoming results.
Roche (RHHBY) Presents Encouraging Data on MS Drug Ocrevus
by Zacks Equity Research
Roche (RHHBY) announces encouraging data on multiple sclerosis (MS) drug Ocrevus which reinforced the efficacy of drug in the long run.
Shire (SHPG) Turns Down Takeda's Third Buyout Proposition
by Zacks Equity Research
Shire (SHPG) declines Takeda Pharmaceutical's third acquisition offer in a cash-stock deal.
What's in the Cards for Glaxo (GSK) This Earnings Season?
by Zacks Equity Research
Strong sales in Glaxo's (GSK) Pharmaceuticals and Vaccines business segment might aid the company's results in Q1.
Novartis (NVS) Reports Encouraging Data on MS Candidate
by Zacks Equity Research
Novartis (NVS) announces encouraging results from a phase III study, EXPAND, on siponimod (BAF312) in patients with secondary progressive multiple sclerosis.
J&J, Novartis' Q1 Earnings Impress: Will Others Follow Suit?
by Zacks Equity Research
Johnson & Johnson (JNJ) and Novartis reported strong first-quarter 2018 earnings results earlier this week.
Novartis (NVS) Beats Earnings and Revenue Estimates in Q1
by Zacks Equity Research
Novartis reported encouraging results for the first quarter as sales and earnings both topped expectations on Cosentyx and Entresto strength.
Sanofi to Divest European Generic Unit, Streamline Business
by Zacks Equity Research
Sanofi (SNY) announces sale of its European generic unit, Zentiva, for $2.4 billion.
Roche Hemophilia Drug Gets Breakthrough Therapy Designation
by Zacks Equity Research
The FDA grants Breakthrough Therapy Designation to Roche's (RHHBY) Hemlibra for treatment of people with hemophilia A without factor VIII inhibitors.
Amgen's Aimovig Reduces Episodic Migraine in 30% Patients
by Zacks Equity Research
Amgen (AMGN) releases full data from the phase IIIb trial, evaluating the efficacy and safety of Aimovig on patients suffering episodic migraine with multiple treatment failures.
What's in Store for Novartis (NVS) This Earnings Season?
by Zacks Equity Research
We expect investors to focus on the performance of newly launched drugs when Novartis (NVS) reports its first-quarter results.
Gilead (GILD) Presents Encouraging Data on NASH Therapies
by Zacks Equity Research
Gilead Sciences (GILD) announces encouraging data from a proof-of-concept study on experimental combination NASH therapies at The International Liver Congress 2018 in Paris.
Pharma Stock Roundup: NVS to Buy AveXis, PFE & ABBV's Drugs Succeed in Phase III
by Zacks Equity Research
Novartis (PFE) to buy AveXis for $8.7 billion. Merck's (MRK) Keytruda succeeds in another key lung cancer study. AbbVie's (ABBV) upadacitinib met endpoints in the 4th phase III study from its SELECT program.
Rigel Pharmaceuticals' (RIGL) Stock Gains 16%: Here's Why
by Zacks Equity Research
Shares of Rigel (RIGL) rise given that the FDA's decision on its lead pipeline candidate Tavalisse is nearing.
Bristol-Myers Collaborates With Harvard Fibrosis Network
by Zacks Equity Research
Bristol-Myers (BMY) announces a research collaboration agreement with Harvard Fibrosis Network to discover and develop potential new therapies for fibrotic diseases, including fibrosis of the liver and heart.
Gene Therapy in Limelight on Novartis Deal: 3 Stocks in Focus
by Zacks Equity Research
With the announcement of Novartis (NVS) acquiring AveXis, a clinical stage gene therapy company, several companies have started to develop the therapy with many of them having promising candidates in their pipelines.
Pharma M&A Active This Week: 4 Potential Buyout Targets
by Indrajit Bandyopadhyay
Novartis and Alexion announce respective acquisitions of AveXis and Wilson Therapeutics for a pipeline boost. We suggest four stocks as hot acquisition picks this year.
Glaxo to Sell Rare Disease Gene Therapies to Private Biotech
by Zacks Equity Research
Glaxo (GSK) will divest its rare disease gene therapy drugs to private biotech Orchard Therapeutics in exchange for a 19.9% stake in the company as well as a seat on its board.